Myocarditis in adolescents and young adults following the administration of coronavirus disease 2019 (COVID‐19) mRNA vaccines has been reported.

Vaccination of 12–16‐year‐old adolescents with Comirnaty (tozinameran, Pfizer–BioNTech) and Spikevax (elasomeran, Moderna) was approved in Australia on 22 July 2021 and 3 September 2021 respectively.

In this report, we describe the initial diagnosis, imaging findings, and short term outcomes for adolescents who presented with COVID‐19 vaccine‐associated myocarditis to the Monash Children’s Hospital, a tertiary center in Melbourne with a pediatric cardiology service.

The Monash Health human research ethics committee (QA/81618/MonH‐2021‐291293) approved the study.

We included adolescents (12–18 years old) who presented with typical symptoms of myocarditis associated with troponin rise (> 15 ng/L) within 28 days of first or second doses of COVID‐19 mRNA vaccines during 1 August – 31 December 2021.

Read More